Understanding narcolepsy and other disorders of excessive daytime sleepiness
Narcolepsy type 1 (NT1), previously called narcolepsy with cataplexy, is a chronic neurological disorder caused by loss of hypocretin (orexin)-producing neurons in the lateral hypothalamus.
The lateral hypothalamus contains approximately 70,000 neurons that produce hypocretin-1 and hypocretin-2 (also called orexin-A and orexin-B), neuropeptides crucial for maintaining wakefulness and stabilizing sleep-wake transitions. In NT1, 85-95% of these neurons are lost, likely through autoimmune destruction.
Loss of hypocretin signaling results in inability to maintain stable wakefulness and dysregulation of REM sleep. REM sleep intrudes into wakefulness (causing cataplexy, sleep paralysis, hypnagogic hallucinations) and wake intrudes into sleep (causing sleep fragmentation).
Overwhelming, irrepressible sleepiness despite adequate nighttime sleep. Patients experience frequent involuntary sleep attacks throughout the day. Brief naps (15-20 minutes) are typically refreshing but benefit lasts only 1-2 hours.
Sudden, bilateral loss of muscle tone triggered by strong emotions (typically laughter, but also surprise, anger, excitement). This is partial REM atonia intrusion into wakefulness—the hallmark of NT1.
Characteristics:
Cataplexy is virtually diagnostic of NT1 when present.
Sleep paralysis is the inability to move or speak when falling asleep or waking up, representing REM atonia persisting into transitional sleep-wake states. Episodes last seconds to minutes with preserved consciousness (often terrifying).
Hypnagogic/hypnopompic hallucinations are vivid, often frightening, dream-like perceptual experiences when falling asleep or waking, representing REM dream imagery intruding into wakefulness. Can be visual, auditory, tactile, or vestibular.
The MSLT is the standard objective test for narcolepsy, performed the day after overnight PSG. Protocol includes five nap opportunities at 2-hour intervals throughout the day. Measures mean sleep latency and number of sleep-onset REM periods (SOREMPs).
NT1 findings:
For valid MSLT: adequate sleep (≥6 hours) on preceding PSG, sleep-wake schedule stabilized for 1-2 weeks before testing, medications affecting sleep/REM discontinued (antidepressants for ≥2 weeks, stimulants for ≥1 week), and urine drug screen negative.
Lumbar puncture with CSF hypocretin-1 measurement is highly specific for NT1. Hypocretin-1 ≤110 pg/mL or <1/3 of mean normal values is diagnostic of NT1 with ~99% specificity. This test is particularly useful when cataplexy is unclear or MSLT results are ambiguous.
NT1 is a lifelong condition requiring chronic treatment. No cure exists, but symptoms can be effectively managed.
The most effective treatment for cataplexy. Also improves sleepiness, nighttime sleep, sleep paralysis, and hypnagogic hallucinations.
SSRIs, SNRIs, or tricyclics (clomipramine, venlafaxine) can suppress cataplexy but are less effective than sodium oxybate and may worsen sleepiness.
NT1 treatment should be individualized. Some patients need only sleepiness management, others need cataplexy treatment, and many need both. Start with behavioral interventions and scheduled naps. Add wake-promoting agent for sleepiness. Add sodium oxybate or antidepressant if cataplexy is problematic. Regular follow-up is essential.
NT2 has excessive daytime sleepiness with MSLT findings (mean sleep latency ≤8 minutes, ≥2 SOREMPs) but NO cataplexy and normal CSF hypocretin-1. The pathophysiology is unclear and may be heterogeneous. Some patients later develop cataplexy and transition to NT1.
Treatment is similar to NT1 for sleepiness (wake-promoting agents, scheduled naps) but sodium oxybate is typically not needed since there is no cataplexy.
IH is characterized by excessive daytime sleepiness with mean sleep latency ≤8 minutes on MSLT but <2 SOREMPs (distinguishing it from narcolepsy).
Additional features often include:
Pathophysiology is unknown. CSF hypocretin is normal. IH is a diagnosis of exclusion after ruling out other causes of sleepiness.
Treatment includes maintaining consistent sleep-wake schedule, avoiding sleep deprivation, strategic caffeine use, and wake-promoting medications (modafinil, armodafinil, solriamfetol, pitolisant, or traditional stimulants). Response to treatment is often less robust than in narcolepsy.
Klein-Levin Syndrome (KLS) is a rare disorder characterized by recurrent episodes of severe hypersomnia (sleeping 15-21 hours per day during episodes) lasting days to weeks, with intervening periods of completely normal sleep and function.
During episodes, patients also experience:
KLS typically begins in adolescence with male predominance. Episodes occur 1-20 times per year initially, then decrease in frequency over years before resolving (median duration of illness ~14 years). Between episodes, patients are completely normal.
Treatment is challenging. Lithium may reduce episode frequency and severity in some patients. Stimulants can be used during episodes to improve alertness but don't shorten episodes. Most patients gradually improve over time without specific treatment.
Learn more about sleep testing used in diagnosing hypersomnolence disorders
An overnight PSG is typically the first step before an MSLT. Learn what to expect during the polysomnography process.
Read article → Sleep HealthMake sense of the abbreviations and numbers in your sleep study report so you can have a more informed conversation with your sleep physician.
Read article →